6533b7dcfe1ef96bd12729f7
RESEARCH PRODUCT
Optimum combination therapy regimens for HIV/HCV infection
Patrice MuretDavid ReyLionel Pirothsubject
Microbiology (medical)medicine.medical_specialtyCombination therapyHIV InfectionsHepatic ComplicationAntiviral AgentsMicrobiologyMen who have sex with men03 medical and health sciences0302 clinical medicineVirologyInternal medicineGenotypemedicineHumansDrug Interactions030212 general & internal medicineStage (cooking)Coinfectionbusiness.industryvirus diseasesHepatitis Cmedicine.diseaseHepatitis CInfectious DiseasesImmunologyCoinfectionDrug Therapy Combination030211 gastroenterology & hepatologyHepatic fibrosisbusinessdescription
HIV-HCV co-infection mostly affects intravenous drug users, in whom prevalence has tended to decrease in recent years, while it has increased in men who have sex with men, with occurrence of acute hepatitis C. Hepatitis C has a poorer prognosis in patients co-infected with HIV, as clinical progression is faster and degree of hepatic fibrosis is greater. However, optimized ARV treatment is clearly associated with slower progression to hepatic complications. Interactions between HCV and HIV drugs are numerous, which underlines the importance of pharmacological advice for HIV-treated patients before they start HCV treatment. In HIV-HCV co-infection, treatment of hepatitis C has to be offered as in mono-infected patients (US and European countries) or to all patients (French guidelines). In most patients, HCV eradication is achieved with different DAA associations, the choice and duration being driven by HCV genotype, hepatic fibrosis stage, and whether patients have been previously treated or not.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2016-01-30 | Expert Review of Anti-infective Therapy |